Literature DB >> 8501143

Activation of the somatotropic axis by testosterone in adult males: evidence for the role of aromatization.

A J Weissberger1, K K Ho.   

Abstract

To determine whether testosterone modulates the somatotropic axis in adult males, we compared 24-h GH secretion (from 20-min sampling, using Cluster analysis) and insulin-like growth factor-I (IGF-I) levels of five hypogonadal men (aged 20-32 yr) with those of six normal men (aged 21-27 yr), and examined the effects of testosterone replacement (testosterone enanthate 250 mg im monthly). To elucidate whether the action of testosterone on the somatotropic axis is direct, or requires the aromatization of testosterone to estradiol, we also examined the effects of the nonsteroidal antiestrogen, tamoxifen (20 mg/day for 3 weeks), on 24-h GH secretion and IGF-I levels in the normal men and in four of the hypogonadal men during concurrent testosterone treatment. Compared to the normal men, the hypogonadal men had significantly reduced mean GH pulse amplitude (3.1 +/- 0.6 vs. 8.4 +/- 1.7 micrograms/L, P < 0.05), but not pulse frequency. Testosterone treatment resulted in a significant increase in 24-h mean serum GH (0.7 +/- 0.2 to 1.4 +/- 0.2 micrograms/L, P < 0.05), mean GH pulse amplitude (3.1 +/- 0.6 to 5.2 +/- 0.8 micrograms/L, P < 0.01) and serum IGF-I (0.9 +/- 0.1 to 1.1 +/- 0.1 U/mL, P < 0.05). In the normal men, tamoxifen significantly reduced 24-h mean serum GH (1.1 +/- 0.3 to 0.5 +/- 0.1 micrograms/L, P < 0.05), mean GH pulse amplitude (8.4 +/- 1.7 to 4.7 +/- 0.4 micrograms/L, P < 0.05), and serum IGF-I (1.0 +/- 0.1 to 0.7 +/- 0.1 U/mL, P < 0.001). In the hypogonadal men on testosterone replacement, tamoxifen lowered 24-h mean serum GH (1.3 +/- 0.2 to 0.6 +/- 0.2 micrograms/L, P < 0.01), mean GH pulse amplitude (5.5 +/- 1.0 to 2.4 +/- 0.8 micrograms/L, P < 0.01), and serum IGF-I (1.2 +/- 0.1 to 0.8 +/- 0.1 U/mL, P < 0.05). We conclude that testosterone plays an important role in the modulation of the male somatotropic axis in adulthood, as appears to be the case in puberty, and that this effect is partly dependent on the aromatization of testosterone to estradiol.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8501143     DOI: 10.1210/jcem.76.6.8501143

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  29 in total

1.  Determinants of dual secretagogue drive of burst-like growth hormone secretion in premenopausal women studied under a selective estradiol clamp.

Authors:  Dana Erickson; Daniel M Keenan; Leon Farhy; Kristi Mielke; Cyril Y Bowers; Johannes D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

Review 2.  Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.

Authors:  J D Veldhuis; W S Evans; C Y Bowers; S Anderson
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

3.  Effect of Testosterone on FGF2, MRF4, and Myostatin in Hypogonadotropic Hypogonadism: Relevance to Muscle Growth.

Authors:  Husam Ghanim; Sandeep Dhindsa; Manav Batra; Kelly Green; Sanaa Abuaysheh; Nitesh D Kuhadiya; Antoine Makdissi; Ajay Chaudhuri; Paresh Dandona
Journal:  J Clin Endocrinol Metab       Date:  2019-06-01       Impact factor: 5.958

4.  The effects of clonidine on blood pressure, catecholamine and growth hormone release in hypogonadal men is preserved and not influenced by testosterone replacement therapy.

Authors:  G Del Rio; C Carani; A Velardo; M Procopio; G Zizzo; P Savio; R Mantovani; P Marrama; E Ghigo
Journal:  J Endocrinol Invest       Date:  1996-09       Impact factor: 4.256

5.  Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice.

Authors:  O Vidal; M K Lindberg; K Hollberg; D J Baylink; G Andersson; D B Lubahn; S Mohan; J A Gustafsson; C Ohlsson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

6.  Hormone and genetic study in male to female transsexual patients.

Authors:  F Lombardo; L Toselli; D Grassetti; D Paoli; P Masciandaro; F Valentini; A Lenzi; L Gandini
Journal:  J Endocrinol Invest       Date:  2013-01-14       Impact factor: 4.256

7.  Testosterone supplementation in older men restrains insulin-like growth factor's dose-dependent feedback inhibition of pulsatile growth hormone secretion.

Authors:  Johannes D Veldhuis; Daniel M Keenan; Joy N Bailey; Adenborduin Adeniji; John M Miles; Remberto Paulo; Mihaela Cosma; Cacia Soares-Welch
Journal:  J Clin Endocrinol Metab       Date:  2008-11-04       Impact factor: 5.958

8.  Locally produced estrogen through aromatization might enhance tissue expression of pituitary tumor transforming gene and fibroblast growth factor 2 in growth hormone-secreting adenomas.

Authors:  Hande Mefkure Ozkaya; Nil Comunoglu; Fatma Ela Keskin; Buge Oz; Ozlem Asmaz Haliloglu; Necmettin Tanriover; Nurperi Gazioglu; Pinar Kadioglu
Journal:  Endocrine       Date:  2015-11-17       Impact factor: 3.633

9.  Endogenous Estrogen Regulates Somatostatin-Induced Rebound GH Secretion in Postmenopausal Women.

Authors:  Johannes D Veldhuis; Dana Erickson; Rebecca Yang; Paul Takahashi; Cyril Bowers
Journal:  J Clin Endocrinol Metab       Date:  2016-07-26       Impact factor: 5.958

10.  Factors other than sex steroids modulate GHRH and GHRP-2 efficacies in men: evaluation using a GnRH agonist/testosterone clamp.

Authors:  Johannes D Veldhuis; Cyril Y Bowers
Journal:  J Clin Endocrinol Metab       Date:  2009-04-07       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.